Summary sheet
Construction of a multi-purpose production facility for vaccines and diagnostics at Statens Serum Institut.
The project will increase SSI’s existing capacity for the development and production of vaccines and the carrying out of associated R&D.
The project will not materially change current practice within the dedicated vaccine producing area. Other related activities will be carried out within existing facilities, making use of existing laboratories, pilot plants and clinical centres; an EIA is therefore not explicitly required under EU Directive 97/11. The promoter’s general compliance with environmental regulations whether the authorities have requested an EIA for the new facility will be verified during appraisal.
The promoter is a State-owned enterprise and, as such, the following EC Directives on procurement apply: Directive 92/50 on service supply, Directive 93/37 on public works and Directive 93/96 on goods supply. Procedures for procuring specialised equipment and external services will be verified during appraisal.
Pharmaceutical.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications